SCHEMBL20535669

SCHEMBL20535669

O=Cc1ccc(Sc2ccc3ccccc3c2)cc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
SIRT3 Q9NTG7 1/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
MAPK1 P28482 1/20 0.42
MCL1 Q07820 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HAO1 Q9UJM8 1/20 0.41
CYP2A6 P11509 1/20 0.38
ANPEP P15144 1/20 0.37
MAP2K2 P36507 1/20 0.37
MAP2K1 Q02750 1/20 0.37
G6PD P11413 1/20 0.36
CCR6 P51684 1/20 0.36
HKDC1 Q2TB90 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279052 0.78 TDP1 (0.44) LMNASMN1; SMN2KMT2AMAPTNPSR1
SCHEMBL3253021 0.78 TERT (0.45) LMNAKMT2AKDM4EMAPTPKM
SCHEMBL12375092 0.77 TERT (0.43) LMNAKMT2AMAPTNPSR1HAO1
SCHEMBL3674814 0.76 PTGER3 (0.45) LMNASMN1; SMN2SIRT2SIRT1SIRT3
SCHEMBL31241186 0.76 PTGER3 (0.45) LMNASMN1; SMN2SIRT2SIRT1SIRT3
SCHEMBL30832956 0.75 LMNA (0.57) LMNASMN1; SMN2SIRT2SIRT1SIRT3
SCHEMBL761802 0.75 LMNA (0.57) LMNASMN1; SMN2SIRT2SIRT1SIRT3
SCHEMBL5113076 0.75 RAB9A (0.50) LMNASMN1; SMN2SIRT2SIRT1SIRT3
SCHEMBL15105262 0.74 LMNA (0.46) LMNAKMT2ACYP2A6PRKDCALDH1A1
SCHEMBL2280933 0.73 MAPT (0.50) LMNASMN1; SMN2KMT2AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS LMNA 4243/4885SMN1; SMN2 4200/4885SIRT2 2241/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS LMNA 2918/4885SMN1; SMN2 2458/4885SIRT2 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.